Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 2Phase 1/2 2

Status

Recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1CNS 1

Conditions

Prostatic Neoplasms 12Lymphoma, Non-Hodgkin 8Wilms Tumor 7Sarcoma 7Glioma 7Rhabdoid Tumor 6Neuroectodermal Tumors, Primitive, Peripheral 6Neuroblastoma 6Multiple Myeloma 6Medulloblastoma 6Lymphoma 6Histiocytosis, Langerhans-Cell 6Hepatoblastoma 6Ependymoma 6Rhabdomyosarcoma 5Osteosarcoma 5Central Nervous System Neoplasms 5Pancreatic Neoplasms 4Mouth Neoplasms 4Leukemia, Myeloid, Acute 4Colorectal Neoplasms 4Breast Neoplasms 4Sarcoma, Ewing 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Thyroid Cancer, Papillary 2

Interventions

Oxaliplatin 67Capecitabine 60Fluorouracil 58Bevacizumab 54Gemcitabine 51Paclitaxel 50Leucovorin 50Irinotecan 40Docetaxel 39Carboplatin 39Cisplatin 38pembrolizumab 37Nivolumab 37Cetuximab 35Sunitinib 25Trastuzumab 24Radiosurgery 24Radiotherapy 21Doxorubicin 21Cyclophosphamide 21Panitumumab 20Drug Therapy 19Pemetrexed 18Everolimus 18Sorafenib 17Interleukin-2 16Fulvestrant 16Albumin-Bound Paclitaxel 16atezolizumab 15Erlotinib Hydrochloride 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Neoplasm Metastasis × X-Rays × Clear all
NCT05327010 2026-05-13

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
88 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05222620 2026-04-13

SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial

Mayo Clinic

Phase 2 Recruiting
90 enrolled
CNS

Brain Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡